All In Biotech

Free tool

FAERS Monitor: Eryped

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 050207 or its brand name (Eryped, Erythromycin Ethylsuccinate). Reports on generic versions are filed under their own applications.

Reports

609

Serious

361

59% of reports

Hospitalization

149

Death reported

35

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug hypersensitivity72
  • vomiting45
  • nausea41
  • diarrhoea36
  • off label use34
  • rash24
  • dyspnoea23
  • hypersensitivity22
  • product use in unapproved indication22
  • abdominal pain21
  • pruritus21
  • urticaria17
  • drug ineffective16
  • malaise16
  • anxiety15

Reports by year received

View as table
YearReports
200413
200511
20068
20075
200815
200913
201030
201126
201217
201335
201421
201517
201645
201737
201846
201953
202032
202130
202213
202331
202445
202545
202621

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,550 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
drug hypersensitivitySignal7212.910.3782
hypersensitivitySignal224.12.749
urticariaSignal173.52.228
vomitingSignal453.32.572
abdominal painSignal213.12.028
product use in unapproved indicationSignal223.12.029
diarrhoea361.91.416
rash241.91.310
pruritus211.91.28
anxiety151.81.15
nausea411.81.314
dyspnoea231.40.92
off label use341.31.03
malaise161.30.81
drug ineffective160.40.313

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.